NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
46-60 of 388
Advancing Pediatric MS Care: Insights from AAN 2026
NeuroFrontiersAdvancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Family Planning in Patients with Multiple Sclerosis
NeuroFrontiersFamily Planning in Patients with Multiple Sclerosis
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiersEarly ALS Patients Show Slowed Decline with Pridopidine Treatment
Rethinking Progression in Multiple Sclerosis
NeuroFrontiersRethinking Progression in Multiple Sclerosis
Charles Turck, PharmD, BCPS, BCCCP
Christopher Lock, MD
- advertisement
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiersThe Burden of Cognitive Dysfunction in Multiple Sclerosis
Christopher Lock, MD
Christopher Lock, MD
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiersWho’s Missing from Multiple Sclerosis Research?
Ashley Baker, MSN, PMHNP
Ruth Ann Marrie, MD, PhD
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiersCK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiersGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiersMultiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Raphael Schneider, MD, PhD, FRCPC, CIP
- advertisement
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiersAdvancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Adil Harroud, MD
Dylan Hamitouche
Ryan Quigley
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiersMultiple Sclerosis Without Borders: Taking a Global View
Andrew Wilner, MD, FACP, FAAN
Victor Rivera, MD
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiersUnderstanding Accelerated Biological Aging in Pediatric MS
Jennifer Yang, MD
